To me the biggest risk would be perhaps considerably lower market cap than the current valuation being placed on Zenith privately. For me, I would not want to see Zenith go public unless it was around some kind of transformational news that would place Zenith on every biotech investor’s radar and put the stock in a position of being in very high demand. JMO